- •Novel BRCA2 mutations in two Lebanese families.
- •Variable expressivity within family members.
- •Haploinsufficiency and/or mutation-specific dominant negative phenotypes.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA.Nat Struct Mol Biol. 2010; 17: 1263-1265https://doi.org/10.1038/nsmb.1905
- BRCA1 and BRCA2: different roles in a common pathway of genome protection.Nat Rev Cancer. 2011; 12: 68-78https://doi.org/10.1038/nrc3181
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers.Nat Med. 2013; 19: 1381-1388https://doi.org/10.1038/nm.3369
- Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.Breast Cancer Res BCR. 2009; 11: R47https://doi.org/10.1186/bcr2334
- Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.Mol Cancer Res MCR. 2009; 7: 1304-1309https://doi.org/10.1158/1541-7786.MCR-09-0149
- Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.Cell. 2011; 145: 529-542https://doi.org/10.1016/j.cell.2011.03.041
- Replication fork reversal triggers fork degradation in BRCA2-defective cells.Nat Commun. 2017; 8: 859https://doi.org/10.1038/s41467-017-01164-5
- Modifiers of risk of hereditary breast cancer.Oncogene. 2006; 25: 5832-5836https://doi.org/10.1038/sj.onc.1209870
- BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.Cancer. 2009; 115: 2222-2233https://doi.org/10.1002/cncr.24200
- Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.JAMA. 2017; 317: 2402-2416https://doi.org/10.1001/jama.2017.7112
- Hereditary cancer predisposition syndromes.J Clin Oncol Off J Am Soc Clin Oncol. 2005; 23: 276-292https://doi.org/10.1200/JCO.2005.10.042
- Hereditary breast and ovarian cancer: review and future perspectives.J Mol Med Berl Ger. 2006; 84: 16-28https://doi.org/10.1007/s00109-005-0696-7
- BRCA1 mutations in a population-based sample of young women with breast cancer.N Engl J Med. 1996; 334: 137-142https://doi.org/10.1056/NEJM199601183340301
- Meta-analysis of BRCA1 and BRCA2 penetrance.J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25: 1329-1333https://doi.org/10.1200/JCO.2006.09.1066
- Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.J Clin Oncol Off J Am Soc Clin Oncol. 2004; 22: 735-742https://doi.org/10.1200/JCO.2004.05.055
- BRCA1 and BRCA2 mutations and the risk for colorectal cancer.Clin Genet. 2015; 87: 411-418https://doi.org/10.1111/cge.12497
- KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer.Cancers. 2017; 9https://doi.org/10.3390/cancers9050042
- BRCA2 is required for homology-directed repair of chromosomal breaks.Mol Cell. 2001; 7: 263-272
- The BRC Repeats of BRCA2 Modulate the DNA-binding selectivity of RAD51.Cell. 2009; 136: 1032-1043https://doi.org/10.1016/j.cell.2009.02.019
- PALB2 is an integral component of the BRCA complex required for homologous recombination repair.Proc Natl Acad Sci U S A. 2009; 106: 7155-7160https://doi.org/10.1073/pnas.0811159106
- Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.Breast Cancer Res Treat. 2009; 117: 161-165https://doi.org/10.1007/s10549-008-0249-1